港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

496.720

-5.792-1.15%

漲家數：6

跌家數：25

平家數：2

市盈率：- -

高：507.303

開：502.573

低：495.158

收：502.512

成交量：8,175.03萬

成交額：18.06億

市值：3,152.73億

流通市值：2,806.09億

資料載入中...

總覽新聞資訊

市場持續縮量或臨近變盤，網絡安全概念與創新藥成結構性亮點

勁方醫藥-B(02595.HK)：GFH375(口服KRAS G12D抑制劑)II期單藥治療經治NSCLC優效數據登陸2026世界肺癌大會口頭報告

勁方醫藥-B(02595)：GFH375(口服KRAS G12D抑制劑)II期單藥治療經治NSCLC優效數據登陸2026世界肺癌大會口頭報告

亞盛醫藥與北京大學達成戰略合作，共築血液腫瘤協同創新體系

智通港股早知道 | 國產創新藥WCLC數據密集兑現投行看好中國CRO/CDMO復甦明確

對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內

每日经济新闻

創新藥板塊迎來近一個月最大漲幅，這些國產創新藥在「2026世界肺癌大會」讀出亮眼數據

每日经济新闻

億騰嘉和(06998.HK)9月14日斥資約170.16萬港元回購100萬股

CRO板塊強勢走高！多家CRO上市公司解密業務近況

微博财经-财道工作室

智通港股解盤 | 美國放緩AI另有玄機 WCLC大會再度催化創新藥

心瑋醫療-B(06609)授出56萬份股份獎勵

康寧傑瑞製藥-B(09966)9月14日耗資約79.63萬港元回購9.9萬股

董事會主席兼首席執行官倪昕增持億騰嘉和(06998)20萬股每股作價約1.74港元

智通财经网

縮量震盪下，創新藥逆市爆發，中證銀行指數上探年內新高！光模塊回調，高「光」ETF獲資金逢低關注

董事會主席吳以芳增持雲頂新耀(01952)8000股每股作價26.9港元

智通财经网

德琪醫藥-B(06996.HK)因受限制股份單位獲歸屬而發行合共1009萬股

董事長兼總裁吳豫生增持同源康醫藥-B(02410)17萬股每股作價約2.7港元

智通财经网

ETF日報：短期看在A股整體市場動能偏弱、熱點輪動加快的環境下，前期調整的創新藥、CXO板塊擁有一定性價比

康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書

國家醫保局公布價格招採信用評價「特別嚴重失信」和「嚴重失信」名單

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK1574/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":496.71994,"timestamp":1789459707407,"preClose":502.51205,"halted":0,"volume":81750325,"delay":0,"changeRate":-0.011526,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-5.792114,"latestTime":"09-15 16:00:00","open":502.57327,"high":507.303,"low":495.15784,"amount":1806018702,"amplitude":0.024169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":3.744174,"peRate":166.585651,"turnoverRate":0.00304,"increases":7,"decrements":24,"flats":1,"marketCap":315273116400,"floatMarketCap":280608949080},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":507.303,"amplitude":0.024169,"preClose":502.51205,"low":495.15784,"pbRate":"3.744174","latestPrice":496.71994,"volume":81750325,"delay":0,"open":502.57327,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":518.573,"twentyDayClose":502.603,"sixtyDayClose":431.958,"secType":"PLATE","market":"HK","turnoverRate":0.00304,"peRate":166.585651,"marketCap":315273116400,"floatMarketCap":280608949080,"timestamp":1789459707407,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667697929","title":"市場持續縮量或臨近變盤，網絡安全概念與創新藥成結構性亮點","url":"https://stock-news.laohu8.com/highlight/detail?id=2667697929","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667697929?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 09:28","pubTimestamp":1789435718,"startTime":"0","endTime":"0","summary":"　　昨日市场延续弱势震荡，三大指数全线收跌，量能进一步萎缩，仅剩1.63万亿，通常而言持续缩量震荡后市场面临着变盘节点，静待后续的方向选择。　　网络安全概念成为昨日市场最大亮点，逆势走出独立走强行情。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/zldongxiang/20260915/32369725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LOUP","BK1161","SPAM","159992","IBBQ","SKYY","BK4588","DRES","HAKY","FWD","GSFP","ANEW","BPAY","WCBR","NSI","BK1574","MVPS","TEKX","BUG","KOMP","CRWC","XT","BCTK","CRTC","BK4585","FDIF","NBDS","PSWD","CRWL","MEDX","UCYB","IHAK","06978","LNGR","TEK","TEKY","CIBR","FITE","PSCT","INVN","USMD","FDFF","EIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667694130","title":"勁方醫藥-B(02595.HK)：GFH375(口服KRAS G12D抑制劑)II期單藥治療 經治NSCLC優效數據登陸2026世界肺癌大會口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2667694130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667694130?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 08:24","pubTimestamp":1789431858,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1515","09939","02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134694","title":"勁方醫藥-B(02595)：GFH375(口服KRAS G12D抑制劑)II期單藥治療 經治NSCLC優效數據登陸2026世界肺癌大會口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134694","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134694?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 08:24","pubTimestamp":1789431858,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，GFH375单药治疗经治KRASG12D突变型非小细胞肺癌的II期试验更新数据，于当地时间9月14日登陆今年在首尔举行的世界肺癌大会口头报告。截至2026年9月4日，共有75名KRASG12D突变型NSCLC患者接受600mgQD口服GFH375治疗，其中98.7%的患者存在远处转移，包括骨转移、脑转移(16%)、肝转移等。截至2026年6月17日，75名患者接受GFH375单药治疗后显示安全性/耐受性可控。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02595","09939","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690236","title":"亞盛醫藥與北京大學達成戰略合作，共築血液腫瘤協同創新體系","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690236","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690236?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:40","pubTimestamp":1789429200,"startTime":"0","endTime":"0","summary":"双方将整合临床资源与创新研发优势，共筑血液肿瘤协同创新体系，加快该领域创新成果的临床转化，为患者带来更多获益。北京大学人民医院作为北大医学体系的重要组成部分和国家医学中心建设单位，在血液肿瘤等重大疾病诊疗与研究领域积淀深厚。亚盛医药一直以来与北京大学有着深厚的合作根基与相互的信任。\" 此次战略合作标志着亚盛医药与北京大学在血液肿瘤领域的协同创新进入新阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5046875_ZH46875_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5046875_ZH46875_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","06855","BK1574","AAPG","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691412","title":"智通港股早知道 | 國產創新藥WCLC數據密集兑現 投行看好中國CRO/CDMO復甦明確","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691412?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:29","pubTimestamp":1789428595,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。经初步测算，本次交易完成后，一汽股份将成为公司第二大和具有战略影响力的股东;本次交易预计构成重大资产重组及关联交易，不构成公司实际控制人变更，不构成重组上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008369823.USD","IE0008368742.USD","06871","LU1226287875.USD","BK1574","BK1183","LU1328277881.USD","CDMO","BK4139","BK1539","LU2039709279.SGD","IBBQ","01911","LU1960683339.HKD","06978","LU1951186391.HKD","02238","LU0501845795.SGD","BK1147","IE00B543WZ88.USD","LU1226287792.SGD","SG9999004220.SGD","159992","LU0315179316.USD","VXUS","BK1144","IE00BZ08YT58.USD","LU1813983027.USD","BK1161","02889","BK1119","BK4588","LU1226288170.HKD","LNGR","KCAI","LU1008478684.HKD","LU0140636845.USD","LU0326950275.SGD","HK0000165453.HKD","LU1152091754.HKD","LU1226287529.USD","MEDX","LU0314109678.HKD","01093","KURE","BK1191","LU1993786604.SGD","BK4585","BK1521","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667660668","title":"對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內","url":"https://stock-news.laohu8.com/highlight/detail?id=2667660668","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667660668?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 01:03","pubTimestamp":1789405401,"startTime":"0","endTime":"0","summary":"2026年上半年，中国创新药延续高增长态势。国家药监局数据显示，2026年1~6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。《每日经济新闻》记者（以下简称每经记者）注意到，从上市公司半年报来看，首付款作为部分企业BD（商务拓展）收入的一部分，让利润表短暂“翻红”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153873800338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153873800338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","MEDX","IE00B5TLWC47.USD","LU2272731865.HKD","06978","LU1992135472.HKD","IBBQ","BK1161","BK4588","LU2272731782.SGD","PPH","LU2322448957.HKD","159992","LU2272731600.USD","LU2473716301.USD","LU2322448791.USD","LU1992135399.USD","XPH","IBB","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667366424","title":"創新藥板塊迎來近一個月最大漲幅，這些國產創新藥在「2026世界肺癌大會」讀出亮眼數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2667366424","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667366424?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 22:40","pubTimestamp":1789396854,"startTime":"0","endTime":"0","summary":"9月14日，低迷了近一个月的创新药板块迎来上涨。截至收盘，创新药（BK1106）、创新药（HK1105）分别上涨2.38%、3.42%。个股方面，诺诚健华、映恩生物、乐普生物、康方生物领跑港股。消息面上，9月12日—15日召开的“2026世界肺癌大会（WCLC）”成为板块最强催化，多家国产药企密集交出重磅临床数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873752330.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873752330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","IBBQ","159992","BK1161","MEDX","LNGR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667664958","title":"億騰嘉和(06998.HK)9月14日斥資約170.16萬港元回購100萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667664958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667664958?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 22:28","pubTimestamp":1789396096,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","BK1583","06998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667466104","title":"CRO板塊強勢走高！多家CRO上市公司解密業務近況","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466104","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466104?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 21:08","pubTimestamp":1789391280,"startTime":"0","endTime":"0","summary":"在互动平台与机构调研中，多家具备CRO业务的上市公司近期密集回应市场关切，披露了订单、产能及全球化布局的最新进展。2026 年上半年，公司实现 CRO 销售收入 4,513.95 万元， 较上年同期增长 10.91%。截至 2026 年上半年末，客户群体不断扩大，累计服务超过 16,900 家研发实验室客户。CRO 业务毛利率基本保持相对稳定水平，具体受服务类型、项目内容影响有所波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-14/doc-inirveaq9305051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4231","NETL","BK4080","BK1574","MEDX","ADC","IBBQ","06978","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667666143","title":"智通港股解盤 | 美國放緩AI另有玄機 WCLC大會再度催化創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667666143?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 20:45","pubTimestamp":1789389921,"startTime":"0","endTime":"0","summary":"科技股的走弱，和 Anthropic、OpenAI 与 SpaceX 罕见联手集体呼吁放缓AI 开发步伐有关。业绩方面，多光谱 AI 大模型服务收入冲到 3.20 亿元，同比暴涨 382.5%，收入占比直接从 29.8% 飙升至 78%。机构认为，2026 年 WCLC 大会的主角仍是 IO2.0 与 ADC，肺癌领域尤其是 1L 非小细胞肺癌的标准治疗范式正处于迭代前夜，国产双抗与 ADC 的进度全球领先。授权品种的里程碑付款与商业化分成，正在成为创新药企业价值兑现的第二曲线。这是公司首款双抗 ADC 获批临床，也是公司第三款 ADC 创新药进入临床。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0877626530.USD","MEDX","BK1574","BK1566","IE00BGHQDM52.EUR","KCAI","LU0640798160.USD","IBBQ","LU0821914370.USD","IE00BZ08YS42.EUR","LNGR","IE00B29SXG58.USD","KURE","00135","LU1969619763.USD","BK1521","06978","LU0651946864.USD","VXUS","09969","IE00BMCWC346.EUR","IE0034224299.USD","ARTY","02688","LU0593848301.USD","IE00BPRC5H50.USD","LU0287142896.SGD","BK1500","06160","IE0008369823.USD","IE00BZ08YT58.USD","CHAT","LU1051768304.USD","06690","LU1515016050.SGD","IE00BZ08YR35.GBP","LU0431992006.USD","LU0348735423.USD","LU1224709979.USD","AGIX","01193","159992","AIPO","VTHR","LU1808992512.USD","BK1161","BK4588","QTOC","LU0307460666.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667719665","title":"心瑋醫療-B(06609)授出56萬份股份獎勵","url":"https://stock-news.laohu8.com/highlight/detail?id=2667719665","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667719665?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 20:23","pubTimestamp":1789388635,"startTime":"0","endTime":"0","summary":"智通财经APP讯，心玮医疗-B(06609)发布公告，于2026年9月14日，本公司根据本公司于2025年5月26日采纳并经不时修订的2025年H股激励计划(2025年H股激励计划)，向本集团雇员(承授人)授出56万份股份奖励(奖励)(2026年9月授出)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1587","BK1100","06609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667469668","title":"康寧傑瑞製藥-B(09966)9月14日耗資約79.63萬港元回購9.9萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667469668","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667469668?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:23","pubTimestamp":1789384984,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)公布，2026年9月14日耗资约79.63万港元回购9.9万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667663590","title":"董事會主席兼首席執行官倪昕增持億騰嘉和(06998)20萬股 每股作價約1.74港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667663590","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667663590?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:10","pubTimestamp":1789384234,"startTime":"0","endTime":"0","summary":"9月10日，董事会主席兼首席执行官倪昕增持亿腾嘉和(06998)20万股，每股作价1.7445港元，总金额约为34.89万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260914/20260914191110_45297.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260914/20260914191110_45297.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","BK1583","BK1161","06998","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668966","title":"縮量震盪下，創新藥逆市爆發，中證銀行指數上探年內新高！光模塊回調，高「光」ETF獲資金逢低關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668966","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668966?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:10","pubTimestamp":1789384200,"startTime":"0","endTime":"0","summary":"AI硬件赛道普遍回调，受硅谷“降速”言论影响，光模块龙头承压明显，高“光”创业板人工智能ETF华宝标的指数收跌2%，资金逢低关注布局机会。分红方面，国有六大行2026年度中期现金分红总额拟超2000亿元，同时为进一步增强投资者的获得感，均将中期拟分红比例由30%提高至31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-iniruxuu7290017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK1161","LNGR","159253","BK4588","AAOZ","BK1574","FDN","IBBQ","BK4550","LUMA","LYTE","AAOX","399986","AAOG","159992","MEDX","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667667063","title":"董事會主席吳以芳增持雲頂新耀(01952)8000股 每股作價26.9港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667667063","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667667063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:08","pubTimestamp":1789384113,"startTime":"0","endTime":"0","summary":"9月11日，董事会主席吴以芳增持云顶新耀(01952)8000股，每股作价26.9港元，总金额为21.52万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260914/20260914190902_80115.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260914/20260914190902_80115.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","EWH","BK1161","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668325","title":"德琪醫藥-B(06996.HK)因受限制股份單位獲歸屬而發行合共1009萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668325","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668325?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:07","pubTimestamp":1789384054,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","06996","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667670666","title":"董事長兼總裁吳豫生增持同源康醫藥-B(02410)17萬股 每股作價約2.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667670666","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667670666?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:07","pubTimestamp":1789384024,"startTime":"0","endTime":"0","summary":"9月11日，董事长兼总裁吴豫生增持同源康医药-B(02410)17万股，每股作价2.7036港元，总金额约为45.96万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260914/20260914190726_24966.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260914/20260914190726_24966.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09939","159938","EWH","BK1574","BK1161","BK1515","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667685646","title":"ETF日報：短期看在A股整體市場動能偏弱、熱點輪動加快的環境下，前期調整的創新藥、CXO板塊擁有一定性價比","url":"https://stock-news.laohu8.com/highlight/detail?id=2667685646","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667685646?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:02","pubTimestamp":1789383720,"startTime":"0","endTime":"0","summary":"形成赛道级利好共振，重塑市场对创新药研发进度与商业化价值的预期，修复创新药β行情，抬升CXO产业链订单与研发景气度预期。前期创新药、CXO板块经历持续回调，整体估值与市场情绪充分降温，板块点位回落至6-8月宽幅震荡箱体下沿位置，具备一定的技术性反弹空间。展望后市，短期看，在A股整体市场动能偏弱、热点轮动加快、反弹逐步收敛的环境下，前期调整的创新药、CXO板块拥有一定性价比。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-iniruxuw4057482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","83130","159992","02827","06978","02846","BK4550","159982","FDN","03188","399300","03130","IBBQ","BK1574","07233","BK1147","BK1161","MEDX","WX","CXO","LNGR","82846","BK4585","83188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657414","title":"康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657414","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657414?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，于2026年9月11日，创新药CMS-D001片获得中国国家药品监督管理局签发的药物临床试验批准通知书，于2026年9月14日收到药物临床试验批准通知书。NMPA同意集团开展临床试验以评价CMS-D001治疗系统性红斑狼疮适应症的有效性和安全性。CMS-D001作为高选择性TYK2抑制剂，相较于泛JAK抑制剂，CMS-D001对其他JAK家族激酶的影响较小，可在长期疾病控制中维持疗效并降低相关安全风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BYV24P56.USD","IE00BVYPNQ40.USD","BMED","SG9999004311.SGD","PSYK","BK1161","LNGR","IBBJ","SG9999015986.USD","LU2488822045.USD","159992","00867","06978","IE00BMCWC346.EUR","SG9999015945.SGD","SG9999015952.SGD","BK1574","BK1593","IE00BVYPNP33.GBP","IBBQ","MEDX","BK1191","SG9999004220.SGD","IE00BGHQDM52.EUR","SG9999015978.USD","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667983650","title":"國家醫保局公布價格招採信用評價「特別嚴重失信」和「嚴重失信」名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2667983650","media":"央视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667983650?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:00","pubTimestamp":1789380000,"startTime":"0","endTime":"0","summary":"受国家医疗保障局委托，国家医疗保障局医药价格和招标采购指导中心汇总了截至2026年7月1日各省份评级为“特别严重失信”和“严重失信”的医药企业情况，现公告如下。注3：价格招采信用评级主要依据行贿金额、不正当价格行为、扰乱集中采购秩序等严重程度进行确定。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruxuu7272468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":2,"totalSize":348,"code":"91000000","status":"200"}]}}